Retention and effectiveness of secukinumab in psoriasis patients in real world setting

Not Applicable

Completed

• Conditions: psoriasis vulgaris

• Registration Number: jRCT1080225042
• Lead Sponsor: Novartis Pharma K.K.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2020-01-29
• Last Update Posted: 2022-10-14

Recruitment & Eligibility

• Status: completed
• Sex: All
• Target Recruitment: 120

Inclusion Criteria

1.Patients who provide informed consent (written or oral) for study participation 2.Age >=20 at study participation 3.Patients with a documented diagnosis of psoriasis vulgaris with or without PsA and were/are treated with secukinumab according to the Japanese package insert of secukinumab 4.Psoriasis with or without PsA patients who started secukinumab at the participating dermatology institutions after 26-Dec-2014 and whose first day of secukinumab treatment is >52 weeks before the IC collection date

Exclusion Criteria

1.Patients whose follow-up visit to the participating institution is <2 after secukinumab initiation

Study & Design

• Study Type: Observational
• Study Design: multicenter, retrospective, non-interventional study

Primary Outcome Measures

Name	Time	Method
retention rate at Week 52	Week 52	The estimate of retention rate (the proportion of patients who do not discontinue secukinumab) at Week 52 will be derived.
time to discontinuation of secukinumab		The primary endpoint is the time to discontinuation of secukinumab in psoriasis with or without PsA patients followed at medical institutions participating in this study.

Trial Locations

Locations (1)

Japan; Location not specified

Japan